Key Takeaways
- Broad-based 89% YoY revenue surge: Growth spanned all four segments, with pharma up 3x and performance materials up over 2x, driven by new molecule ramp-ups and contract commercializations.
- Working capital inflection promised: Inventory is beginning to decline and customer advances are flowing in; management expects a sharp reduction in net working capital days this year, with a few hundred crores of absolute reduction.
- Balance sheet reset complete: The company used INR175 crores from a preferential issue to repay term debt and is now long-term net debt free, with a target to push debt-to-EBITDA below 1.5x.
- Japan MPA opens a new growth vector: A long-term master purchase agreement with a Japanese fluorochemicals leader covers multiple niche molecules for semiconductors and electronics, with commercialization starting this year.
- What to watch next quarter: Whether the promised sharp inventory reduction materializes, the pace of Japan MPA commercialization, and any clarity on the fluid U.S. tariff situation.
Revenue Recovery & Segment Performance
- Pharma leads the rebound: Revenue grew 3x YoY as 17 new molecules launched over the last 18 months, primarily KSMs for CNS, statins and infectious disease therapies, began ramping up. These are extensions of existing chemistry and supply chains, not LOI-based revenue.
- Performance materials doubles: Over 2x YoY growth came from commercializing products under recently signed contracts, with the segment expected to reach 15-20% of revenue this year and 20-25% in the next 2-3 years.
- Agrochem rebounds sharply: 100% YoY growth, a reversal from last year's degrowth, attributed to product-specific and customer-specific dynamics rather than a uniform industry recovery.
- Customer destocking eases: Over the last 18 months, customers focused on reducing supply inventory levels, and those stocks are now approaching target levels. Cost pressures from energy and logistics have also stabilized, though customers still press for cheaper products.
Thakkar: "No doubt always customer will want to have a cheaper product and quicker. But I think everybody has seen that now we have come to a level where we need to get to business on a steady-state basis."
Working Capital & Balance Sheet
- Inventory liquidation begins: Existing inventory will be used to fulfill a substantial number of orders in Q2, converting stock into sales and reducing absolute working capital. Receivables days are also expected to contract.
- Cash conversion cycle shrinking: Management targets a return to 2024 working capital levels over the year, with net working capital reaching 180 days over the next two years and an absolute reduction of a few hundred crores.
- Net term debt eliminated: INR175 crores from the July 2025 preferential issue was used to repay term debt, leaving the company practically net zero on a net term debt basis. Total debt is expected to stay in the INR1,000 crores range and decline further as operating cash flows kick in.
- Leverage target: Debt-to-EBITDA is to be kept below 2x, with a push toward 1.5x or less.
New Contracts & Strategic Expansion
- Japan MPA details: A long-term master purchase agreement with a Japan-based multinational conglomerate, a global leader in fluorochemicals, covers multiple niche molecules for semiconductors, data centers and electronics. Several molecules are scheduled for commercialization this year, with production ramping up from next year.
- Scope and value undisclosed: Management declined to share the annual value or exact molecule count, stating only that it is working on more than 5-6 products with "significantly large potential" in the specialty polymer segment.
- E-Lyte LOI: A letter of intent with E-Lyte Innovations, a European electrolyte solutions developer for energy storage, positions Anupam as one of the first manufacturers to commercially produce this molecule in India.
- Two additional agreements: Signed with Japan and U.S.-based multinational companies, details not disclosed.
Desai: "This collaboration not only highlights Anupam's strength in fluorination and custom synthesis, but also reflects the trust global customers place in our quality manufacturing and technical capabilities."
LOI Execution & Growth Visibility
- LOI revenue doubling: INR450-500 crores expected from LOIs this year, double last year's level, with similar growth projected for next year.
- Overall revenue growth: Management is confident in over 30% revenue growth this year, with strong performance across all four segments, citing the last two quarters as empirical evidence.
- Incremental margin profile: New business is expected to carry a 25-27% margin profile.
Thakkar: "If you look at my last 2 quarters' results, it gives me that much confidence and it provides a strong empirical evidence to that plan or the suggestion that I'm making."
Tariffs & External Risks
- U.S. tariff situation fluid: Management declined to make a conclusive statement on the impact of U.S. tariffs, calling the situation too fluid to assess.
- Export share corrected: Export share was corrected to 58% after a typographical error in the presentation.
Thakkar: "If we look at the situation in terms of tariff from the U.S. one, I think today, a lot is fluid, I would say. And I would wait before make a conclusive statement."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Working capital reduction | Sharp reduction in inventory and net working capital days; absolute reduction of a few hundred crores | FY26, starting from Q2 |
| Net working capital days | Reach 180 days | Over the next 2 years |
| Revenue growth | Over 30% YoY | FY26 |
| LOI revenue | INR450-500 crores, doubling from last year | FY26 |
| Performance materials mix | 15-20% of revenue | FY26 |
| Performance materials mix | 20-25% of revenue | Next 2-3 years |
| Japan MPA commercialization | Several molecules commercialized, production ramp-up follows | Commercialization this year, ramp-up from next year |
| Debt-to-EBITDA | Below 2x, pushing toward 1.5x or less | Not specified |
| Incremental margins | 25-27% on new business | Not specified |
| Tax rate | Historical average | Ongoing |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Consolidated revenue | ₹491 cr, +89% YoY |
| Consolidated revenue from operations | ₹486 cr, +91% YoY vs ₹254 cr in Q1 FY25 |
| Consolidated EBITDA including other income | ₹129 cr, +118% YoY vs ₹59 cr in Q1 FY25; margin 26.3% |
| Consolidated profit after tax | ₹49 cr, +297% YoY vs ₹12 cr in Q1 FY25; margin 10% |
| Standalone revenue from operations | ₹316 cr, +93% YoY vs ₹164 cr in Q1 FY25 |
| Standalone EBITDA including other income | ₹99 cr, +133% YoY vs ₹43 cr in Q1 FY25; margin 31% |
| Standalone profit after tax | ₹29.7 cr, vs ₹1.4 cr in Q1 FY25; margin 9.3% |
| Order book | ₹14,646 cr |
| Life sciences-related specialty chemicals revenue share | 88% of total revenue |
| Pharma segment revenue share | 24% of total revenue, vs 15% in Q1 FY25; 3x growth YoY |
| Performance materials revenue share | 12% of total revenue, vs 10% in Q1 FY25; over 2x growth YoY |
| Agrochem revenue share | ~57% of total revenue |
| Export share | 58% of revenue from operations |
| Top 10 customer concentration | 79% of revenue from operations |
| Gross debt | ~₹1,000 cr |
| Interest expense run rate | ₹26–27 cr per quarter |
| Debt-to-EBITDA | less than 2x, targeting 1.5x or less |
| Working capital cycle target | 180 days over the next 2 years |
| FY26 revenue growth expectation | over 30% |
| LOI contribution expected in FY26 | ₹450–500 cr |
| Incremental margin guidance | 25–27% |
| Effective tax rate in Q1 FY26 | 23%, lower due to credits |